Clinical Trials

143 enrolled 16 charts

Anal Canal Carcinoma, Anus Neoplasms

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Prostatic Neoplasms

NCT03210714 2026-04-22

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloid

20 enrolled 10 charts

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03303846 2026-04-22

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

Phase NA Active not recruiting

344 enrolled

Healthy Subject

NCT03866382 2026-04-22

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04082520 2026-04-22

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

42 enrolled

Meningioma

NCT04267848 2026-04-22

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

1,210 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT04402788 2026-04-22

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Phase 2/3 Recruiting

138 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04665739 2026-04-22

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT04858334 2026-04-22

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

152 enrolled

Pancreatic Acinar Cell Carcinoma

NCT05030298 2026-04-22

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Phase 1 Recruiting

28 enrolled

Glioma

NCT05087888 2026-04-22

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

Terminated

9 enrolled

Brain Neoplasms

NCT05099003 2026-04-22

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Phase 1/2 Recruiting

132 enrolled

Glioma

NCT05198830 2026-04-22

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

42 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT05507541 2026-04-22

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

10 enrolled

Phase 1 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05627245 2026-04-22

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05638295 2026-04-22

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

105 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05675410 2026-04-22

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT05987241 2026-04-22

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

992 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06126276 2026-04-22

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

70 enrolled

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT06649812 2026-04-22

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06948786 2026-04-22

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

22 enrolled

Lymphoma, Follicular

NCT06961084 2026-04-22

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

62 enrolled

Head & Neck

Thyroid Neoplasms

NCT07042295 2026-04-22

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

NCT07061964 2026-04-22

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07061977 2026-04-22

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Recruiting

336 enrolled

Gynecologic

Locally Advanced Cervical Adenocarcinoma

NCT07226453 2026-04-22

PNOC041

30 enrolled

Posterior Fossa Ependymal Tumor

NCT07544992 2026-04-22

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Phase 1 Not yet recruiting

24 enrolled

Phase NA Active not recruiting

Astrocytoma, Glioblastoma

NCT01507428 2026-04-21

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

Phase 2 Completed

138 enrolled 42 charts

Stage III Lung Non-Small Cell Cancer AJCC v7

NCT02194738 2026-04-21

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

99 enrolled

Breast

HER2/Neu Negative

NCT02600949 2026-04-21

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Phase 1 Recruiting

300 enrolled